1. Home
  2. Targets
  3. Collagen alpha-2(IV) chain

Tbio Collagen alpha-2(IV) chain

Canstatin, a cleavage product corresponding to the collagen alpha 2(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity. It inhibits proliferation and migration of endothelial cells, reduces mitochondrial membrane potential, and induces apoptosis. Specifically induces Fas-dependent apoptosis and activates procaspase-8 and -9 activity. Ligand for alphavbeta3 and alphavbeta5 integrins.

This gene encodes one of the six subunits of type IV collagen, the major structural component of basement membranes. The C-terminal portion of the protein, known as canstatin, is an inhibitor of angiogenesis and tumor growth. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. [provided by RefSeq, Jul 2008]

 Comments

Property Summary

NCBI Gene PubMed Count 98
PubMed Score 76.60
PubTator Score 57.52

Knowledge Summary

Patent

No data available

TINX Plot

  Disease (7)

Disease Target Count Z-score Confidence
Carcinoma 11493 0.0 0.9
Disease Target Count Z-score Confidence
Alport syndrome 21 3.506 1.8
Disease Target Count
PORENCEPHALY 2 1

Expression

  Differential Expression (38)

Disease log2 FC p
adult high grade glioma 1.200 5.3e-03
Astrocytoma, Pilocytic 1.800 6.1e-06
atypical teratoid / rhabdoid tumor 1.800 3.4e-05
autosomal dominant Emery-Dreifuss muscul... 1.193 3.2e-02
Becker muscular dystrophy 1.678 3.2e-03
Breast cancer 3.000 2.4e-02
cystic fibrosis -1.408 4.3e-06
dermatomyositis 1.400 4.5e-02
Duchenne muscular dystrophy 1.641 4.8e-06
ductal carcinoma in situ -1.200 4.1e-03
ependymoma 2.400 8.5e-03
gastric carcinoma 1.600 8.1e-03
glioblastoma 1.900 1.3e-06
group 3 medulloblastoma 1.300 9.6e-03
head and neck cancer and chronic obstruc... 1.100 2.5e-02
Hydrolethalus syndrome 1.452 4.1e-02
interstitial cystitis 2.300 1.4e-04
intraductal papillary-mucinous adenoma (... -1.800 4.4e-03
intraductal papillary-mucinous carcinoma... -1.800 2.1e-02
intraductal papillary-mucinous neoplasm ... -1.800 4.8e-02
invasive ductal carcinoma -1.100 1.1e-02
juvenile dermatomyositis 2.002 2.9e-11
limb girdle muscular dystrophy 2A 1.069 4.6e-03
lung adenocarcinoma 1.168 1.9e-03
malignant mesothelioma -1.400 1.9e-06
medulloblastoma, large-cell 1.300 9.0e-04
nasopharyngeal carcinoma 2.200 1.8e-07
oligodendroglioma 1.100 1.7e-03
osteosarcoma 2.090 1.9e-02
ovarian cancer 3.000 1.9e-06
pancreatic cancer 2.800 5.6e-05
pancreatic ductal adenocarcinoma liver m... 2.129 7.9e-03
periodontitis 1.200 8.8e-25
primitive neuroectodermal tumor 1.400 3.6e-03
psoriasis 2.200 4.1e-04
pterygium 1.100 3.6e-03
ulcerative colitis 1.300 5.7e-03
urothelial carcinoma 3.500 3.2e-07

Synonym

Accession P08572 Q14052 Q548C3 Q5VZA9 Q66K23
Symbols ICH
POREN2

Gene

COL4A2

PDB

1LI1  

  Ortholog (1)

Species Source Disease
Chimp OMA EggNOG

 UniProt Keyword (16)

See all...

 GO Function (1)

 GO Component (5)

 GO Process (8)

 Compartment GO Term (37)

See all...

 OMIM Phenotype (2)

 MGI Phenotype (5)

 GWAS Trait (8)

 HCA RNA Cell Line (56)

See all...

Pathway (38)

See all...

Protein-protein Interaction (1)

COL4A1  

Gene RIF (40)

AA Sequence 

MGRDQRAVAGPALRRWLLLGTVTVGFLAQSVLAGVKKFDVPCGGRDCSGGCQCYPEKGGRGQPGPVGPQG      1 - 70
YNGPPGLQGFPGLQGRKGDKGERGAPGVTGPKGDVGARGVSGFPGADGIPGHPGQGGPRGRPGYDGCNGT     71 - 140
QGDSGPQGPPGSEGFTGPPGPQGPKGQKGEPYALPKEERDRYRGEPGEPGLVGFQGPPGRPGHVGQMGPV    141 - 210
GAPGRPGPPGPPGPKGQQGNRGLGFYGVKGEKGDVGQPGPNGIPSDTLHPIIAPTGVTFHPDQYKGEKGS    211 - 280
EGEPGIRGISLKGEEGIMGFPGLRGYPGLSGEKGSPGQKGSRGLDGYQGPDGPRGPKGEAGDPGPPGLPA    281 - 350
YSPHPSLAKGARGDPGFPGAQGEPGSQGEPGDPGLPGPPGLSIGDGDQRRGLPGEMGPKGFIGDPGIPAL    351 - 420
YGGPPGPDGKRGPPGPPGLPGPPGPDGFLFGLKGAKGRAGFPGLPGSPGARGPKGWKGDAGECRCTEGDE    421 - 490
AIKGLPGLPGPKGFAGINGEPGRKGDRGDPGQHGLPGFPGLKGVPGNIGAPGPKGAKGDSRTITTKGERG    491 - 560
QPGVPGVPGMKGDDGSPGRDGLDGFPGLPGPPGDGIKGPPGDPGYPGIPGTKGTPGEMGPPGLGLPGLKG    561 - 630
QRGFPGDAGLPGPPGFLGPPGPAGTPGQIDCDTDVKRAVGGDRQEAIQPGCIGGPKGLPGLPGPPGPTGA    631 - 700
KGLRGIPGFAGADGGPGPRGLPGDAGREGFPGPPGFIGPRGSKGAVGLPGPDGSPGPIGLPGPDGPPGER    701 - 770
GLPGEVLGAQPGPRGDAGVPGQPGLKGLPGDRGPPGFRGSQGMPGMPGLKGQPGLPGPSGQPGLYGPPGL    771 - 840
HGFPGAPGQEGPLGLPGIPGREGLPGDRGDPGDTGAPGPVGMKGLSGDRGDAGFTGEQGHPGSPGFKGID    841 - 910
GMPGTPGLKGDRGSPGMDGFQGMPGLKGRPGFPGSKGEAGFFGIPGLKGLAGEPGFKGSRGDPGPPGPPP    911 - 980
VILPGMKDIKGEKGDEGPMGLKGYLGAKGIQGMPGIPGLSGIPGLPGRPGHIKGVKGDIGVPGIPGLPGF    981 - 1050
PGVAGPPGITGFPGFIGSRGDKGAPGRAGLYGEIGATGDFGDIGDTINLPGRPGLKGERGTTGIPGLKGF   1051 - 1120
FGEKGTEGDIGFPGITGVTGVQGPPGLKGQTGFPGLTGPPGSQGELGRIGLPGGKGDDGWPGAPGLPGFP   1121 - 1190
GLRGIRGLHGLPGTKGFPGSPGSDIHGDPGFPGPPGERGDPGEANTLPGPVGVPGQKGDQGAPGERGPPG   1191 - 1260
SPGLQGFPGITPPSNISGAPGDKGAPGIFGLKGYRGPPGPPGSAALPGSKGDTGNPGAPGTPGTKGWAGD   1261 - 1330
SGPQGRPGVFGLPGEKGPRGEQGFMGNTGPTGAVGDRGPKGPKGDPGFPGAPGTVGAPGIAGIPQKIAVQ   1331 - 1400
PGTVGPQGRRGPPGAPGEMGPQGPPGEPGFRGAPGKAGPQGRGGVSAVPGFRGDEGPIGHQGPIGQEGAP   1401 - 1470
GRPGSPGLPGMPGRSVSIGYLLVKHSQTDQEPMCPVGMNKLWSGYSLLYFEGQEKAHNQDLGLAGSCLAR   1471 - 1540
FSTMPFLYCNPGDVCYYASRNDKSYWLSTTAPLPMMPVAEDEIKPYISRCSVCEAPAIAIAVHSQDVSIP   1541 - 1610
HCPAGWRSLWIGYSFLMHTAAGDEGGGQSLVSPGSCLEDFRATPFIECNGGRGTCHYYANKYSFWLTTIP   1611 - 1680
EQSFQGSPSADTLKAGLIRTHISRCQVCMKNL                                         1681 - 1712
//

Text Mined References (102)

PMID Year Title